首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL23 |
| Uniprot No | Q9NPF7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-328aa |
| 氨基酸序列 | IWELKKDVYV VELDWYPDAP GEMVVLTCDT PEEDGITWTL DQSSEVLGSG KTLTIQVKEF GDAGQYTCHK GGEVLSHSLL LLHKKEDGIW STDILKDQKE PKNKTFLRCE AKNYSGRFTC WWLTTISTDL TFSVKSSRGS SDPQGVTCGA ATLSAERVRG DNKEYEYSVE CQEDSACPAA EESLPIEVMV DAVHKLKYEN YTSSFFIRDI IKPDPPKNLQ LKPLKNSRQV EVSWEYPDTW STPHSYFSLT FCVQVQGKSK REKKDRVFTD KTSATVICRK NASISVRAQD RYYSSSWSEW ASVPCSGSTS GSGKPGSGEG STKGRAVPGG SSPAWTQCQQ LSQKLCTLAW SAHPLVGHMD LREEGDEETT NDVPHIQCGD GCDPQGLRDN SQFCLQRIHQ GLIFYEKLLG SDIFTGEPSL LPDSPVGQLH ASLLGLSQLL QPEGHHWETQ QIPSLSPSQP WQRLLLRFKI LRSLQAFVAV AARVFAHGAA TLSP |
| 预测分子量 | 70 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-23重组蛋白的3篇关键文献及简要摘要：
1. **文献名称**：*Structural and functional insights into IL-23-mediated signaling*
**作者**：J. Schmiedel et al.
**摘要**：通过X射线晶体学解析IL-23重组蛋白与其受体的复合物结构，揭示了IL-23与IL-12的结构差异及其特异性结合机制，为靶向IL-23的抗体药物设计提供了依据。
2. **文献名称**：*IL-23 promotes tumour incidence and growth*
**作者**：D. Langowski et al.
**摘要**：利用重组IL-23蛋白在小鼠模型中证明，IL-23通过激活STAT3信号通路促进炎症相关肿瘤的发生和进展，提示其作为癌症治疗潜在靶点。
3. **文献名称**：*IL-23 is critical for autoimmune inflammation via sustaining Th17 responses*
**作者**：C. Sutton et al.
**摘要**：研究重组IL-23蛋白在自身免疫性疾病中的作用，发现其通过维持Th17细胞的存活和功能，驱动实验性自身免疫性脑脊髓炎(EAE)的病理进程。
4. **文献名称**：*Ustekinumab, a human IL-12/23 monoclonal antibody, for psoriatic arthritis*
**作者**：A. Gottlieb et al.
**摘要**：临床试验验证了靶向IL-23/IL-12的重组单抗ustekinumab治疗银屑病关节炎的疗效，证明抑制IL-23信号可显著改善患者症状及炎症指标。
以上文献涵盖IL-23的结构、功能机制及治疗应用，均为该领域经典研究。
Interleukin-23 (IL-23) is a pro-inflammatory cytokine belonging to the IL-12 family, composed of a unique p19 subunit and a p40 subunit shared with IL-12. Discovered in 2000. IL-23 is primarily secreted by activated dendritic cells, macrophages, and monocytes. It plays a critical role in bridging innate and adaptive immunity by promoting the differentiation and maintenance of T helper 17 (Th17) cells, which drive the production of inflammatory cytokines like IL-17. IL-22. and TNF-α. This axis is central to host defense against extracellular pathogens but is also implicated in autoimmune and chronic inflammatory diseases, including psoriasis, inflammatory bowel disease (IBD), and rheumatoid arthritis.
Recombinant IL-23 protein is engineered using genetic recombination techniques, often expressed in mammalian cell systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications. Purification involves affinity chromatography and stringent quality control to achieve high bioactivity and low endotoxin levels. As a research tool, recombinant IL-23 enables mechanistic studies of Th17-mediated immunity, autoimmune pathology, and therapeutic targeting. In drug development, it serves as a critical antigen for screening and validating IL-23 inhibitors. Notably, monoclonal antibodies targeting the p19 subunit (e.g., risankizumab, guselkumab) have emerged as breakthrough therapies for autoimmune conditions, underscoring IL-23's clinical relevance. Ongoing research explores its role in cancer immunotherapy and infectious diseases, highlighting IL-23 as a versatile target in immunology and medicine.
×
